The addition of a glucocorticoid to the protocol of programmed oocyte retrieval for in-vitro fertilization--a randomized study.

The addition of a glucocorticoid to the protocol of programmed oocyte retrieval for in-vitro fertilization--a randomized study.
复制标题

在体外受精程序化卵母细胞取出方案中添加糖皮质激素——一项随机研究。

DOI:
10.1093/oxfordjournals.humrep.a019454
复制
发表时间:
1996
期刊:
影响因子:
6.1
通讯作者:
Jehoshua Dor
Jehoshua Dor
中科院分区:
医学1区
文献类型:
--
作者:
D. Bider;I. Amoday;Ilan Tur;Alexander Livshits;Jehoshua Dor

文献摘要

被引文献

相似文献

一组78名不孕妇女,诊断为输卵管因素不孕症,参加了一项前瞻性,随机研究,以确定是否添加不同剂量的糖皮质激素的体外受精(IVF)诱导排卵的协议将是有益的。评价卵母细胞数、受精率、血清雌二醇、促黄体生成素和促卵泡激素浓度、胚胎移植数和妊娠率。与对照周期(A组; n = 24)相比,增加0.5 mg(B组; n = 27)的1 mg地塞米松(C组; n = 27),结合研究中IVF患者的程序化取卵方案,证明了等效的结果。对照组的平均获卵数为10.8 +/- 3.9,而B组为11.2 +/- 4.0,C组为10.5 +/- 3.6。受精率分别为69 +/- 21、66 +/- 18和70 +/- 15%。妊娠率分别为20、16和20.8%。在输卵管因素不孕症患者中,在取卵诱导排卵方案中每天添加多达1 mg地塞米松并不能改善总体IVF-胚胎移植结局。
A group of 78 infertile women, diagnosed as having tubal factor infertility only, was enrolled in a prospective, randomized study conducted to determine whether the addition of different doses of glucocorticoids to the protocol of ovulation induction for in-vitro fertilization (IVF) would be beneficial. Oocyte numbers, percentage of fertilization, oestradiol, luteinizing hormone and follicle stimulating hormone serum concentrations, number of embryo transfers and pregnancy rate were evaluated. Compared to control cycles (group A; n = 24), the addition of 0.5 mg (group B; n = 27) of 1 mg dexamethasone (group C; n = 27), combined with the protocol of programmed oocyte retrieval for IVF patients in the study, demonstrated equivalent results. The mean numbers of oocytes retrieved were 10.8 +/- 3.9 in the control group, compared to 11.2 +/- 4.0 in group B and 10.5 +/- 3.6 in group C. The fertilization rates were 69 +/- 21, 66 +/- 18 and 70 +/- 15% respectively. The pregnancy rates were 20, 16 and 20.8% respectively. The addition of up to 1 mg dexamethasone daily to the protocol of ovulation induction for oocyte retrieval did not improve the overall IVF-embryo transfer outcome in patients with tubal factor infertility.